Trump Withdraws Nomination of Heidi Overton as FDA Commissioner

0


The White House on Tuesday withdrew the nomination of Dr. Heidi Overton to lead the Food and Drug Administration, citing a lack of sufficient support in the Senate on the eve of a scheduled committee vote.

A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.” The decision came the night before the Senate Health, Education, Labor and Pensions Committee was set to consider advancing her nomination.

Senate HELP Committee Chairman Bill Cassidy, R-La., disputed the White House’s assessment of the vote count.

Click here to sign up for pro-life news alerts from LifeNews.com

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote on X. “This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate.”

Cassidy later indicated that pro-life senators seeking firm commitments on protecting unborn children were a key point of friction. He said the final hang-up involved pro-life senators seeking assurances from the administration about its commitment to “life issues,” and that the White House withdrew the nomination rather than provide them.

Overton, a preventive medicine physician who has served as deputy director of the White House Domestic Policy Council, was nominated by President Donald Trump in August. Her confirmation faced resistance from pro-life organizations concerned that the administration had not reversed Biden-era rules allowing mail-order abortions that have killed millions of babies and injured tens of thousands of women.

Susan B. Anthony Pro-Life America had urged senators to secure concrete commitments before advancing her nomination.

“Confirmation is not a coronation,” said Erik Baptist, the organization’s senior vice president of legal strategy. “Before Heidi Overton’s nomination moves forward, senators must secure commitments from the administration that it will immediately restore the in-person dispensing requirement for mifepristone and address the serious flaws with the FDA’s mifepristone safety study.”

Baptist noted that “an estimated 15,000 unborn babies a month will die in pro-life states alone thanks to illegal mail-order abortion drugs,” and called it “a tragedy that the Biden-era mail-order abortion drug regime remains in effect.”

During her September confirmation hearing, Overton declined to prejudge the FDA’s review of mifepristone. In earlier writing she has stated that the science is clear that unborn babies are human beings and that advances such as ultrasound have strengthened arguments for protecting them.

The White House is now weighing alternatives, including Sen. Roger Marshall, R-Kan., a pro-life obstetrician-gynecologist who recently lost his reelection bid. A Trump administration official previously told Semafor that Marshall “is viewed as an alternative if Heidi can’t make it through,” noting that “senators have an easier time getting confirmed, traditionally.”

A senior Republican aide said there was “a growing view in the Senate that a senator would be the only person while we’ve got a majority so Roger Marshall’s name is quickly percolating as a person who would be confirmable.”

The FDA has operated under acting leadership since former Commissioner Marty Makary left in May. Republicans hold a narrow majority until January, when Democrats are scheduled to take control of the Senate. The withdrawal leaves limited time to confirm a permanent commissioner before the majority changes.



Source
Las Vegas News Magazine

Leave A Reply

Your email address will not be published.

Are you human? Please solve:Captcha


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More